Table 3.

Subset 2 includes 25 patients with vocal hyperfunction (VH) who participated before and after successful treatment and 10 individuals without VH in the control group who participated for a baseline week of monitoring and a follow-up week of monitoring at least 6 months later.

Subset 2 group	Phase	n	Sex	Age	CAPE-V OS	V-RQOL	Singers (n)	SVHI-10
Patients with VH	Pretreatment	25	23 F, 2 M	23.0 (7.4)	25 (14.1)	67.0 (20.5)	22	22.0 (8.2)
	Posttreatment				14 (10.9)	86.0 (14.2)		11.0 (7.6)
Controls	Baseline	10	10 F, 0 M	22.0 (3.0)	NR	94.3 (6.0)	8	10.6 (4.4)
	6-month follow-up					95.5 (7.4)		4.9 (3.9)

Note. Mean and standard deviation (SD) displayed for age, Overall Severity from the Consensus Auditory–Perceptual Evaluation of Voice (CAPE-V OS), Voice-Related Quality of Life (V-RQOL) scores, number of singers in each group, and Singing Voice Handicap Index-10 (SVHI-10) for those singers. F = female; M = male; NR = not rated.